title: Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options.
abstract: Measles incidence in England and Wales has fallen to an all-time low. Attention is now focused on preventing local outbreaks, and, in the long run, on the elimination of indigenous measles. A realistic age-structured (RAS) mathematical model of measles transmission is used to reconstruct the impact of measles vaccination in England and Wales from 1968 to the present and to evaluate the merits of future policy options. In general, the predictions of the model show good agreement with long-term age stratified case reports and seroprevalence surveys. The model underestimates the proportion of cases that are notified in 0-2-year-old children. However, recent work suggests a high degree of misdiagnosis in this age group. Projections on the basis of the existing vaccination strategy in the UK suggest that the present level of measles vaccine coverage will be insufficient to eliminate small seasonal outbreaks of measles. This result is, however, sensitive to the assumed level of vaccine efficacy. Explorations of a variety of changes to current vaccination strategy favour a 2-dose schedule with the second dose administered at age 4 years irrespective of vaccination history. A vaccination campaign in school-age children, to reduce deficits in herd immunity, would accelerate progress towards measles elimination.
authors.affiliation: Department of Zoology, University of Oxford.
authors.forename: H R
authors.initials: HR
authors.lastname: Babad
authors.forename: D J
authors.initials: DJ
authors.lastname: Nokes
authors.forename: N J
authors.initials: NJ
authors.lastname: Gay
authors.forename: E
authors.initials: E
authors.lastname: Miller
authors.forename: P
authors.initials: P
authors.lastname: Morgan-Capner
authors.forename: R M
authors.initials: RM
authors.lastname: Anderson
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D004198:Disease Susceptibility; D004338:Drug Combinations; D004739:England / Q000453:epidemiology; D006801:Humans; D007115:Immunization Schedule; D015994:Incidence; D007223:Infant; D008457:Measles / Q000453:epidemiology / Q000517:prevention & control*; D008458:Measles Vaccine; D008459:Measles virus / Q000276:immunology; D022542:Measles-Mumps-Rubella Vaccine; D008875:Middle Aged; D015233:Models, Statistical; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D014611:Vaccination; D014852:Wales / Q000453:epidemiology
chemical_list: D000914:Antibodies, Viral; D004338:Drug Combinations; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine